参考文献（References）

［1］ICH Guideline.E2A：Clinical safety data management：definitions and standards for expedited reporting.（1994-10-27）［2019-12-20］.https：//database.ich.org/sites/default/files/E2A_Guideline.pdf.

［2］ICH Guideline.E2D：Post-approval safety data management：definitions and standards for expedited reporting.（2003-11-12）［2019-12-20］.https：//database.ich.org/sites/default/files/E2D_Guideline.pdf.

［3］European Commission.Volume 9A of the rules governing medicinal products in the European Union-guidelines on pharmacovigilance for medicinal products for human use.（2011-10-02）［2019-8-20］.http：//ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en/pdf.

［4］FDA.FDA Code of Federal Regulations，title 21：314.80 Postmarketing reporting of adverse drug experiences.（2019-09-19）［2019-8-20］.https：//www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm.

［5］U.S.Department of Health and Human Services.FDA MedWatch 3500A form（For use by user-facilities，importers，distributors and manufacturers for MANDATORY reporting）.（2008-10-31）［2020-8-27］.https：//www.fda.gov/media/69876/download.

［6］MedDRA MSSO/IFPMA.MedDRA Term Selection：Points to Consider Release 4.19 Based on MedDRA Version 23.0.（2020-03-01）［2020-08-27］.https：//admin.new.meddra.org/sites/default/files/guidance/file/000401_termselptc_r4_19_mar2020.pdf.

［7］MedDRA MSSO/IFPMA.MedDRA Data Retrieval and Presentation：Points to Consider release 3.19 Based on MedDRA Version 23.0.（2020-03-01）［2020-08-27］.https：//admin.new.meddra.org/sites/default/files/guidance/file/000402_datretptc_r3_19_mar2020.pdf.

［8］European Commission.Communication from the Commission-Detailed guidance on the collection，verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use（‘CT-3'）.（2011-11-06）［2020-9-17］.https：//eur-lex.europa.eu/legal-content/EN/TXT/？uri=CELEX：52011XC0611（01）.

［9］HILL A B.The environment and disease：association or causation？ J Roy Soc Med，1965（58）：295-300.

［10］HOWICK J，GLASZIOU P，ARONSON J.The evolution of evidence hierarchies：what can Bradford Hill's guidelines for causation contribute？ J R Soc Med，2009（102）：186-194.

［11］WHO.WHO Uppsala Monitoring Center standadised case causality assessment.（2018-04-06）［2020-08-26］.http：//who-umc.org/Graphics/24734.pdf.

［12］CIOMS Working GroupⅥ on the Management of Safety Information from Clinical Trials，Council for International Organizations of Medical Sciences.Management of safety information from clinical trials：report of CIOMS Working Group Ⅵ.New York：Renouf Pub Co Ltd，2005.

［13］KARCH F E，LASAGNA L.Toward the operational identification of adverse drug reactions.Clin Pharmacol Ther，1977，21（3）：247-254.

［14］KRAMER M S，LEVENTHAL J M，HUTCHINGSON T A，et al.An algorithm for the operational assessment of adverse drug reactions.I.Background，description and instructions for use.JAMA，1979（242）：623-632.

［15］VENULET J，CIUCCI A，BERNEKER G C.Standardized assessment of drug-adverse reaction associations-rationale and experience.Int J Clin Pharmacol ther Toxicol，1980（18）：381-388.

［16］VENULET J，CIUCCI A，BERNEKER G C.Updating of a method for causality assessment of adverse drug reactions.Int J Clin Pharmacol ther Toxicol，1986（24）：559-568.

［17］NARANJO C A，BUSTO U，SELLERS E M，et al.A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther，1981（30）：239-245.

［18］BEGAUD B，EVREUX J C，JOUGLARD J，et al.French imputability method.Therapie，1985（40）：111-118.

［19］JONES J K.Adverse drug reactions in the community health setting：approaches to recognizing，counseling，and reporting.Fam Community Health，1982（5）：58-67.

［20］U.S.Department of Health and Human Services，FDA，Center for Drug Evaluation and Research（CDER），et al.Guidance for industry drug-induced liver injury：premarketing clinical evaluation.（2007-10-12）［2020-8-1］.https：//evs.nci.nih.gov/ftp1/CTCAE/Related/UCM072278.pdf.

［21］European Medicines Agency and Heads of Medicines Agencies.Guidelines on good pharmacovigilance practices（GVP）Module Ⅵ-Management and reporting of adverse reactions to medicinal products.（2013-06-06）［2020-9-17］.https：//www.onacademic.com/detail/journal_1000032564780010_b747.html.

［22］FDA.MedWatch3500 form（For VOLUNTARY reporting of adverse events，product problems and product use errors）.（2019-02-09）［2020-8-1］.http：//www.fda.gov/downloads/Safety/MedWatch/HowToReport/DownloadForms/ucm082728.pdf.